Johnson & Johnson MedTech has announced that new clinical and real-world data from its VARIPULSE Platform, used in pulsed field ablation (PFA) procedures for atrial fibrillation (AF), will be presented at the upcoming Asia Pacific Heart Rhythm Society (APHRS) and Japanese Heart Rhythm Society (JHRS) joint annual meeting. The event will take place from November 12 to 15, 2025, in Yokohama, Japan.
The VARIPULSE Platform is composed of the VARIPULSE Catheter, TRUPULSE Generator, and CARTO 3 Mapping System with VARIPULSE Software. It has received approval for use in the United States, Europe, Asia Pacific, Canada, and Latin America. According to Johnson & Johnson MedTech, over 25,000 procedures using this platform have been performed across several regions including the U.S., Europe, Canada, Japan, Hong Kong, mainland China, Korea, Taiwan, and Australia.
The company states it is committed to advancing scientific understanding and supporting collaborations aimed at improving patient outcomes by sharing new evidence from the VARIPULSE Platform. At APHRS and JHRS meetings, Johnson & Johnson MedTech will also conduct symposia and educational sessions featuring hands-on demonstrations.
Jing Li, Vice President of Electrophysiology & Neurovascular for Asia Pacific MedTech at Johnson & Johnson said: “The clinical evidence we’re presenting at this year’s APHRS and JHRS—highlighting our fully integrated-by-design CARTO 3 Mapping System and VARIPULSE Platform for pulsed field ablation—alongside a robust scientific program, immersive tech-suite experience, and forward-looking pipeline discussions, reflects our deep commitment and the comprehensive strength of our leading portfolio for atrial fibrillation and complex arrhythmias.”
Key presentations include data from several studies:
- QUEST AF: An oral presentation on acute success rates of persistent AF ablation using a temperature-controlled high-power short-duration radiofrequency catheter.
- VARIPURE (SECURE): A poster on workflow efficiency and vein-level analysis with a novel PFA variable loop circular catheter in AF procedures.
- admIRE: Sessions addressing age impact on sex differences in one-year outcomes after catheter ablation for AF as well as same-day discharge procedural characteristics following PFA treatment.
- REAL AF: Several sessions analyzing markers of ablation efficacy in AF such as right-sided first pass isolation; bilateral first pass isolation as a procedural endpoint; benefits of carina ablation; left atrial scar burden differences by sex; and outcome variations based on sex after catheter ablation.
Johnson & Johnson MedTech indicated ongoing collaboration with clinicians to further develop real-world evidence around the VARIPULSE Platform.
The company’s cardiovascular portfolio offers advanced mapping technologies aimed at treating heart rhythm disorders such as atrial fibrillation. According to their statement on biosensewebster.com , they focus on solutions that address significant unmet needs like heart failure and stroke.
Additional information about their work in innovative medicine and medical technology can be found at https://thenext.jnjmedtech.com .
A cautionary note regarding forward-looking statements advises readers not to rely solely on projections made about future events related to the VARIPULSE Platform due to various risks described in regulatory filings available online or upon request from Johnson & Johnson.
Prior to use of these devices physicians are instructed to review supplied indications along with warnings or precautions. In the United States these devices are restricted by law to sale only by or on order of a physician.